Cumberland Pharmaceutical Inc (CPIX)

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis PR Newswire NASHVILLE, Tenn...

CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA

CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA PR Newswire NASHVILLE, Tenn., May 28, 2026 Commercialization in China...

Form DEFM14A - Definitive proxy statement relating to merger or acquisition

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE PR Newswire NASHVILLE, Tenn., May 5, 2026 Enters into...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE PR Newswire NASHVILLE, Tenn., April 28, 2026...

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex

Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex PR Newswire NASHVILLE, Tenn., April...

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in...

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE PR Newswire...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities